We have previously demonstrated that inhibition of EZH2 in a HER2+ mouse model induces tumor cell expression of endogenous retroviral elements that promote expression of IFNs and sensitize tumors to anti-HER2 targeted therapy (Hirukawa et al., 2019). Here, EZH2 is linked to neoplasm.